Ticker > Company >

Zim Laboratories share price

Zim Laboratories Ltd.

  39.13 K   26   5 BSE: 541400 SECTOR: Pharmaceuticals & Drugs

142.30
+7.75 (5.76%)
BSE: 24 Sep 04:01 PM

Price Summary

Today's High

₹ 142.3

Today's Low

₹ 131.05

52 Week High

₹ 144.85

52 Week Low

₹ 59.72

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 763.56 Cr.

Enterprise Value

₹ 849.39 Cr.

No. of Shares

5.37 Cr.

P/E

201.9

P/B

2.72

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  52.36

CASH

₹ 37 Cr.

DEBT

₹ 122.82 Cr.

Promoter Holding

30.36 %

EPS (TTM)

₹  0.7

Sales Growth

-1.37%

ROE

2.26 %

ROCE

5.64%

Profit Growth

-49.21 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-1.37%
3 Year-2.24%
5 Year4.06%

Profit Growth

1 Year-49.21%
3 Year-37.98%
5 Year1.21%

ROE%

1 Year2.26%
3 Year5.02%
5 Year7.35%

ROCE %

1 Year5.64%
3 Year8.04%
5 Year10.72%

Debt/Equity

0.4326

Price to Cash Flow

16.02

Interest Cover Ratio

1.6363

CFO/PAT (5 Yr. Avg.)

2.64864808936309

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2026 30.36 0.00
Mar 2026 30.35 0.00
Dec 2025 33.26 0.00
Sep 2025 33.26 0.00
Jun 2025 33.26 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 15.7188 days.
  • The company has a good cash flow management; CFO/PAT stands at 2.64864808936309.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 6.99163350338861.

 Limitations

  • The company has shown a poor profit growth of -37.9830050458655% for the Past 3 years.
  • The company has shown a poor revenue growth of -2.2395671345665% for the Past 3 years.
  • Company has a poor ROE of 5.02373333333333% over the past 3 years.
  • The company is trading at a high PE of 201.9.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 71.43 88.39 107.81 102.85 93.05
Total Expenditure 67.09 82.22 95.31 96.28 90.64
Operating Profit 4.34 6.17 12.5 6.58 2.41
Other Income 1.48 2.04 1.71 6.16 0.99
Interest 3.3 3.16 3.43 3.31 3.64
Depreciation 4.79 4.83 4.85 4.9 5.17
Exceptional Items 0 0 0 0 0
Profit Before Tax -2.28 0.23 5.93 4.52 -5.42
Tax -0.59 0.11 1.67 1.24 -1.55
Profit After Tax -1.69 0.12 4.26 3.28 -3.87
Adjusted EPS (Rs) -0.35 0.02 0.87 0.61 -0.72

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 329.49 396.53 365.47 375.64 370.48
Total Expenditure 291.56 345.34 325.37 332.37 340.9
Operating Profit 37.93 51.19 40.1 43.27 29.58
Other Income 4.51 6.43 4.69 5.62 11.39
Interest 8.31 5.58 6.92 11.39 13.2
Depreciation 14.84 16.13 14.83 19.89 19.37
Exceptional Items 0 0 0 0 0
Profit Before Tax 19.3 35.92 23.04 17.61 8.4
Tax 6.28 10.91 6.28 5.87 2.44
Net Profit 13.01 25.01 16.76 11.74 5.97
Adjusted EPS (Rs.) 2.67 5.13 3.44 2.41 1.12

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 16.24 48.73 48.73 48.73 53.5
Total Reserves 153.86 145.45 183.23 195.79 232.85
Borrowings 18.92 24.62 35.6 40.3 41.59
Other N/C liabilities 1.09 12.1 13.05 13.37 11.25
Current liabilities 146.76 110.24 161.9 167.39 186.83
Total Liabilities 336.88 341.15 442.5 465.58 526.03
Assets
Net Block 103.31 107.15 160.49 163.6 160.13
Capital WIP 5.1 17.84 23.52 44.05 58.76
Intangible WIP 6.33 8.42 16.73 21.61 30.64
Investments 8.18 8.18 8.23 13.04 17.66
Loans & Advances 11.64 20.4 15.51 4.97 5.08
Other N/C Assets 0.28 0.52 0.31 0.76 0.5
Current Assets 202.05 178.64 217.71 217.54 253.26
Total Assets 336.88 341.15 442.5 465.58 526.03
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations 19.3 35.92 23.04 17.61 8.4
Adjustment 20.76 20.81 21.36 32.67 27.7
Changes in Assets & Liabilities 7.2 -14.52 -30.36 -0.97 15.16
Tax Paid -0.23 -6.98 -2.57 1.29 -3.6
Operating Cash Flow 47.03 35.23 11.47 50.6 47.66
Investing Cash Flow -14.42 -35.21 -71.94 -41.31 -57.41
Financing Cash Flow -32.97 0.55 59.53 -9.1 28.19
Net Cash Flow -0.36 0.57 -0.94 0.19 18.43

Corporate Actions

Investors Details

Annual Reports

Title Link
Title Link
Annual Report 2026
Annual Report 2023
Annual Report 2022
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit ACUITE RATINGS
Credit ACUITE
Credit ACUITE
Credit ACUITE
Credit CARE
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY23
Concall Q3FY24
Concall Q1FY27
Concall Q1FY24
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY22
Presentation Q4FY22
Presentation Q3FY22
Presentation Q2FY24
Presentation Q1FY25

Company News

Zim Laboratories Stock Price Analysis and Quick Research Report. Is Zim Laboratories an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Zim Laboratories. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Zim Laboratories has a PE ratio of 195.544835414302 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Zim Laboratories has ROA of 1.2031% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Zim Laboratories has a Current ratio of 1.3555.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Zim Laboratories has a ROE of 2.2635%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Zim Laboratories has a Debt to Equity ratio of 0.4326 which means that the company has low proportion of debt in its capital.

  • Sales growth: Zim Laboratories has reported revenue growth of -1.3721% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Zim Laboratories for the current financial year is 7.98420433948795%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Zim Laboratories is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Zim Laboratories is Rs 0.7048. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Zim Laboratories in Ticker for free. Also, one can get the intrinsic value of Zim Laboratories by using Valuation Calculators, which are available with a Finology ONE subscription. 

Zim Laboratories FAQs

Q1. What is Zim Laboratories share price today?
Ans: The current share price of Zim Laboratories is Rs 137.82.

Q2. What is the market capitalisation of Zim Laboratories?
Ans: Zim Laboratories has a market capitalisation of Rs 739.521281616 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Zim Laboratories?
Ans: The PE ratio of Zim Laboratories is 195.544835414302 and the P/B ratio of Zim Laboratories is 2.63231277575109, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Zim Laboratories share?
Ans: The 52-week high share price of Zim Laboratories is Rs 144.49, and the 52-week low share price of Zim Laboratories is Rs 59.31.

Q5. Does Zim Laboratories pay dividends?
Ans: Currently, Zim Laboratories does not pay dividends. Dividend yield of Zim Laboratories is around 0%.

Q6. What are the face value and book value of Zim Laboratories shares?
Ans: The face value of Zim Laboratories shares is Rs 10, while the book value per share of Zim Laboratories is around Rs 52.357. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Zim Laboratories?
Ans: Zim Laboratories has a total debt of Rs 122.8213 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Zim Laboratories?
Ans: The ROE of Zim Laboratories is 2.2635% and ROCE of Zim Laboratories is 5.6423%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Zim Laboratories a good buy for the long term?
Ans: The Zim Laboratories long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Zim Laboratories undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Zim Laboratories appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Zim Laboratories’s financials?
Ans: You can review Zim Laboratories’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Zim Laboratories
X